secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001558370-22-017843
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech reports 17.5% net revenue gain to $59.3M in 9M 2022; gets Nasdaq bid-price deficiency
--------------------------------------------------------------------------------

- Net revenue for nine months ended Sep 30, 2022 was $59.3M, up 17.5% from the same period in 2021.
- Nasdaq notified Fortress that common stock bid price closed below $1.00 for 30 consecutive business days; compliance risk.
- Journey Medical, a partner, generated Q3 2022 total revenue of $16.1M, down from $19.6M in Q3 2021.
- Checkpoint Therapeutics approved a 1-for-10 reverse stock split; Avenue Therapeutics completed a 1-for-15 reverse split in Sep 2022.
- Board declared monthly dividends of $0.1953125 per share on Series A Preferred Stock for Oct, Nov, Dec 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/0001558370-22-017843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837022017843/fbio-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer